BioPharma Dive - Latest News

Bluebird extends deal deadline; Affimed files for insolvency

Shareholders in Bluebird now have a choice of two offers from would-be acquirers Carlyle and SK Capital. Elsewhere, Cytokinetics shared more aficamten data and BridgeBio started a new kind of Attruby trial.

May 14, 2025 - 17:28
 0
Bluebird extends deal deadline; Affimed files for insolvency

Shareholders in Bluebird now have a choice of two offers from would-be acquirers Carlyle and SK Capital. Elsewhere, Cytokinetics shared more aficamten data and BridgeBio started a new kind of Attruby trial.

Read More

Tags:

Previous Article

Novo to work with Septerna in hunt for oral obesity drugs

Next Article

STAT+: GOP embraces MAHA at RFK Jr.’s first House hearing, but raises dissents f...

Related Posts

Innovating a healthier tomorrow: Entering a new era of medicine

Innovating a healthier tomorrow: Entering a new era of ...

May 12, 2025  0

Trump revives ‘most favored nation’ plan in effort to cut US drug prices

Trump revives ‘most favored nation’ plan in effort to c...

May 12, 2025  0

PTC stock slides on new data for Huntington’s drug

PTC stock slides on new data for Huntington’s drug

May 5, 2025  0